Voie souscutanée And NotPaolo Barone
List of bibliographic references
Number of relevant bibliographic references: 18.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 002514 | Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 002708 | Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque] | Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up |
| 002858 | Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients |
| 002881 | Han-Cheng Wang [Taïwan] ; YOLOUNG HSIEH [Taïwan] | Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy |
| 002B12 | F. Birklein [Allemagne] ; F. Erbguth [Allemagne] | Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A : A preliminary observation |
| 002B13 | S. A. Factor [États-Unis] ; D. L. Brown [États-Unis] ; E. S. Molho [États-Unis] | Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson's disease |
| 002C57 | Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Apomorphine : An underutilized therapy for Parkinson's disease |
| 002F10 | T. Van Laar [Pays-Bas] ; B. Van Hilten [Pays-Bas] ; C. Neef [Pays-Bas] ; A. W. F. Rutgers [Pays-Bas] ; S. Pavel [Pays-Bas] ; J. A. Bruijn [Pays-Bas] | The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease : A histologic study |
| 003079 | J. D. O'Sullivan [Australie] ; A. J. Hughes [Australie] | Apomorphine-induced penile erections in Parkinson's disease |
| 003311 | F. Stocchi [Italie] ; M. F. De Pandis [Italie] ; F. A. Delfino [Italie] ; T. Anselmo [Italie] ; D. Frongillo [Italie] | Transient atrial fibrillation after subcutaneous apomorphine bolus |
| 003463 | S. Przedborski [Belgique] ; M. Levivier ; C. Raftopoulos ; A. B. Naini ; J. Hildebrand [Belgique] | Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans |
| 003527 | S. T. Gancher [États-Unis] ; J. G. Nutt [États-Unis] ; W. R. Woodward | Apomorphine infusional therapy in Parkinson's disease : clinical utility and lack of tolerance |
| 003677 | A. J. Hughes [Royaume-Uni] ; S. Bishop ; B. Kleedorfer ; N. Turjanski ; W. Fernandez ; Andrew Lees (neurologue) [Royaume-Uni] ; G. M. Stern | Subcateneous apomorphine in Parkinson's disease: response to chronic administration for up to five years |
| 003754 | U. Bonuccelli [Italie] ; P. Piccini [Italie] ; P. Del Dotto [Italie] ; G. Rossi ; G. U. Corsini ; A. Muratorio [Italie] | Apomorphine test for dopaminergic responsiveness: a dose assessment study |
| 003800 | J.-F. De Saint Victor [France] ; C.-L. Gervason | Levopoda-induced diphasic dyskinesias improved by subcutaneous apomorphine |
| 003936 | M. E. Rodriguez ; M. R. Luquin ; G. Lera ; G. Delgado ; J. M. Salazar ; J. A. Obeso | Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion |
| 003A18 | J. A. Temlett ; N. P. Quinn ; P. G. Jenner ; C. D. Marsden ; E. Pourcher ; A.-M. Bonnet ; Y. Acid ; R. Markstein ; X. Lataste | Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease |
| 003A97 | N. Nomoto ; S. Stahl ; P. Jenner ; C. D. Marsden | Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset |
| This area was generated with Dilib version V0.6.23. |  |